Nigeria is forging ahead with its hydrochloroquine trials for the treatment of covid-19, this is inspite of the announcement by the World Health Organisation suspending the drug test.
The National Agency for Food and Drug Administration and Control (NAFDAC) made this known during our morning programme on TVC earlier today.
On Monday Tedros Ghebreyesus, the WHO director-general, cited the study published by The Lancet, which had examined the effects of the use of hydroxychloroquine alone or when used with a macrolide, and reported a higher mortality rate.
But the NAFDAC DG, Professor Mojisola Adeyeye, said there is data to prove that chloroquine is effective in treating COVID-19 patients, particularly at the “mild stage” of the virus.
She said Nigeria would continue its clinical trials which may take three to four months.
Nigeria is forging ahead with its hydrochloroquine trials for the treatment of covid-19, this is inspite of the announcement by the World Health Organisation suspending the drug test.
The National Agency for Food and Drug Administration and Control (NAFDAC) made this known during our morning programme on TVC earlier today.
On Monday Tedros Ghebreyesus, the WHO director-general, cited the study published by The Lancet, which had examined the effects of the use of hydroxychloroquine alone or when used with a macrolide, and reported a higher mortality rate.
But the NAFDAC DG, Professor Mojisola Adeyeye, said there is data to prove that chloroquine is effective in treating COVID-19 patients, particularly at the “mild stage” of the virus.
She said Nigeria would continue its clinical trials which may take three to four months.
Nigeria is forging ahead with its hydrochloroquine trials for the treatment of covid-19, this is inspite of the announcement by the World Health Organisation suspending the drug test.
The National Agency for Food and Drug Administration and Control (NAFDAC) made this known during our morning programme on TVC earlier today.
On Monday Tedros Ghebreyesus, the WHO director-general, cited the study published by The Lancet, which had examined the effects of the use of hydroxychloroquine alone or when used with a macrolide, and reported a higher mortality rate.
But the NAFDAC DG, Professor Mojisola Adeyeye, said there is data to prove that chloroquine is effective in treating COVID-19 patients, particularly at the “mild stage” of the virus.
She said Nigeria would continue its clinical trials which may take three to four months.
Nigeria is forging ahead with its hydrochloroquine trials for the treatment of covid-19, this is inspite of the announcement by the World Health Organisation suspending the drug test.
The National Agency for Food and Drug Administration and Control (NAFDAC) made this known during our morning programme on TVC earlier today.
On Monday Tedros Ghebreyesus, the WHO director-general, cited the study published by The Lancet, which had examined the effects of the use of hydroxychloroquine alone or when used with a macrolide, and reported a higher mortality rate.
But the NAFDAC DG, Professor Mojisola Adeyeye, said there is data to prove that chloroquine is effective in treating COVID-19 patients, particularly at the “mild stage” of the virus.
She said Nigeria would continue its clinical trials which may take three to four months.
Nigeria is forging ahead with its hydrochloroquine trials for the treatment of covid-19, this is inspite of the announcement by the World Health Organisation suspending the drug test.
The National Agency for Food and Drug Administration and Control (NAFDAC) made this known during our morning programme on TVC earlier today.
On Monday Tedros Ghebreyesus, the WHO director-general, cited the study published by The Lancet, which had examined the effects of the use of hydroxychloroquine alone or when used with a macrolide, and reported a higher mortality rate.
But the NAFDAC DG, Professor Mojisola Adeyeye, said there is data to prove that chloroquine is effective in treating COVID-19 patients, particularly at the “mild stage” of the virus.
She said Nigeria would continue its clinical trials which may take three to four months.
Nigeria is forging ahead with its hydrochloroquine trials for the treatment of covid-19, this is inspite of the announcement by the World Health Organisation suspending the drug test.
The National Agency for Food and Drug Administration and Control (NAFDAC) made this known during our morning programme on TVC earlier today.
On Monday Tedros Ghebreyesus, the WHO director-general, cited the study published by The Lancet, which had examined the effects of the use of hydroxychloroquine alone or when used with a macrolide, and reported a higher mortality rate.
But the NAFDAC DG, Professor Mojisola Adeyeye, said there is data to prove that chloroquine is effective in treating COVID-19 patients, particularly at the “mild stage” of the virus.
She said Nigeria would continue its clinical trials which may take three to four months.
Nigeria is forging ahead with its hydrochloroquine trials for the treatment of covid-19, this is inspite of the announcement by the World Health Organisation suspending the drug test.
The National Agency for Food and Drug Administration and Control (NAFDAC) made this known during our morning programme on TVC earlier today.
On Monday Tedros Ghebreyesus, the WHO director-general, cited the study published by The Lancet, which had examined the effects of the use of hydroxychloroquine alone or when used with a macrolide, and reported a higher mortality rate.
But the NAFDAC DG, Professor Mojisola Adeyeye, said there is data to prove that chloroquine is effective in treating COVID-19 patients, particularly at the “mild stage” of the virus.
She said Nigeria would continue its clinical trials which may take three to four months.
Nigeria is forging ahead with its hydrochloroquine trials for the treatment of covid-19, this is inspite of the announcement by the World Health Organisation suspending the drug test.
The National Agency for Food and Drug Administration and Control (NAFDAC) made this known during our morning programme on TVC earlier today.
On Monday Tedros Ghebreyesus, the WHO director-general, cited the study published by The Lancet, which had examined the effects of the use of hydroxychloroquine alone or when used with a macrolide, and reported a higher mortality rate.
But the NAFDAC DG, Professor Mojisola Adeyeye, said there is data to prove that chloroquine is effective in treating COVID-19 patients, particularly at the “mild stage” of the virus.
She said Nigeria would continue its clinical trials which may take three to four months.
Related posts:
We have revolutionized NAFDAC– Director General, NAFDAC
Nigeria: MFM FC stars, Odey, Olatunbosun set for trials in Belgium
Nigeria ignores W.H.O continues chloroquine clinical test trials
NCRI set to begin trials for modified rice seeds
D.R Congo: Scientists record breakthrough in Ebola treatment after drug trials
FG begins Open Athletics, Football trials across NYSC camps
Huawei gets approval to take part in 5G trials in India
Ebola vaccines arrive in Uganda for trials
